VRTX Q4 2020 Earnings — Vertex Pharmaceuticals Incorporated Revenue & Financial Results | Market Cap Arena

VRTXVertex Pharmaceuticals Incorporated

$129B

Q4 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1.6B+15.2% YoY

Gross Profit

$1.4B87.5% margin

Operating Income

$746M45.8% margin

Net Income

$604M37.1% margin

EPS (Diluted)

$2.30

QoQ Revenue Growth

+5.8%

Cash Flow

Operating Cash Flow

$492M

Free Cash Flow

$444M

Stock-Based Comp.

$97M

Balance Sheet

Total Assets

$11.8B

Total Liabilities

$3.1B

Stockholders' Equity

$8.7B

Cash & Equivalents

$6.0B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1.6B	$1.4B	+15.2%
Gross Profit	$1.4B	$1.2B	+16.0%
Operating Income	$746M	$551M	+35.2%
Net Income	$604M	$583M	+3.6%

Revenue Segments

TRIKAFTA/KAFTRIO

$1.1B67%

ORKAMBI

$215M13%

KALYDECO

$193M12%

SYMDEKO/SYMKEVI

$128M8%

Geographic Segments

UNITED STATES

$1.2B74%

Europe

$360M22%

Other, Non U.S.

$61M4%